Last updated: March 12, 2026
Pliaglis (lidocaine and Tetracaine) is a topical anesthetic cream approved for local anesthesia during superficial dermatological procedures. It is manufactured primarily by Galderma, but distribution and supply chains extend internationally through authorized partners.
Primary Manufacturer
Galderma is the sole developer and manufacturer of Pliaglis. The company holds the patent rights and is responsible for manufacturing, research, and marketing.
Key Points:
- Ownership: Galderma Laboratories, L.P.
- Production Sites: Located primarily in the United States and Switzerland.
- Regulatory Approvals: FDA approval in 2010 (USA), EMA approval in 2012 (Europe).
Authorized Distributors and Supply Chain
Galderma distributes Pliaglis directly within certain markets and partners with select pharmaceutical distributors globally.
Major Regions and Suppliers:
| Region |
Supply Details |
Notes |
| North America |
Direct supply from Galderma's US-based distribution network |
FDA-approved, exclusive distribution rights |
| European Union |
Distributed via authorized partners and local pharmacies |
EMA approval, local licensing required |
| Asia-Pacific |
Distributed through regional partners, limited availability |
Regulatory approvals vary by country |
| Latin America |
Authorized local pharmacies, typically through regional pharmaceutical distributors |
Licensing and import regulations apply |
Key Distribution Partners:
- McKesson (North America): Handles distribution for retail pharmacies.
- Alliance Healthcare (Europe): Responsible for distribution in multiple European countries.
- Other regional distributors: Vary by country, such as Medisca in Canada and regional companies in Asia-Pacific.
Supply Chain Challenges and Considerations
- Regulatory Approvals: Pliaglis requires country-specific approval to be marketed. Not all countries recognize the product, limiting distribution.
- Patent and Exclusivity: Galderma's patent rights extend until at least 2030 in major markets, affecting generic competition.
- Manufacturing Capacity: Limited production sites can cause supply constraints, especially in high-demand periods.
- Import Regulations: Variations in import laws and distribution licenses impact availability in certain regions.
Generic and Alternative Suppliers
As of now, no generic versions of Pliaglis are approved, mainly due to patent protections. However, topical anesthetics with similar compositions contain lidocaine and tetracaine, but they are not marketed under the Pliaglis brand.
Key Takeaways
- Pliaglis is exclusively manufactured by Galderma.
- Distribution is handled directly in the US and via authorized partners in Europe and elsewhere.
- Supply chains are influenced by regulatory hurdles, patent protections, and manufacturing capacity.
- No generic equivalents are authorized; alternative topical anesthetics exist but are different products.
FAQs
1. Who manufactures Pliaglis?
Galderma is the sole manufacturer and rights holder for Pliaglis.
2. Are there authorized generic versions?
No, patent protection prevents generic versions from being marketed legally.
3. Which distributors supply Pliaglis in the US?
McKesson and other regional pharmaceutical distributors supply Pliaglis in North America.
4. Is Pliaglis available in Europe?
Yes. It is distributed through authorized partners following EMA approval.
5. Can Pliaglis be imported into countries without local approval?
Importation is restricted unless the product is authorized locally; import laws vary.
References
- FDA. (2010). Pliaglis approval letter. U.S. Food and Drug Administration.
- EMA. (2012). Pliaglis's summary of product characteristics. European Medicines Agency.
- Galderma. (2023). Product information for Pliaglis.
- Journal of Pharmaceutical Distribution & Logistics. (2021). Topical anesthetic market analysis.
